Keywords: cytrx, buys, innovive, 3m, als, drug, delay

CytRx buys Innovive for $21.3M; ALS drug delay

Article | 16 June 2008

Print This

CytRx has signed a definitive agreement to acquire Innovive Pharmaceuticals, in a deal worth up to $21.3 million. The US drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in